biovu Archives
Genetics and blood pressure
May. 19, 2022—Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.
A clue to an adverse drug event in children
May. 19, 2022—Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.
Gene variants and transplant drug dose
May. 9, 2022—Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.
Gene network linked to Type 2 diabetes
May. 5, 2022—Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.
Calculating risk for uterine fibroids
Apr. 26, 2022—Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.
Major grant renewal to provide five more years of support for VICTR
Apr. 6, 2022—Vanderbilt University Medical Center has competed successfully for a third renewal of its Clinical and Translational Science Award by the National Institutes of Health.
Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development
Jan. 10, 2022—Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU.
Gene discoveries give new hope to people who stutter
Dec. 2, 2021—New research shows the potential to identify therapeutic directions that could improve outcomes for people who stutter.
Initiative helps physicians interpret genetic test results
Sep. 1, 2021—A new institutional initiative will offer a secure and easy way for physicians at Vanderbilt University Medical Center to ask for help interpreting genetic test results for their patients.
For more precise drug treatments, ‘squeeze’ the genome: study finds
Jul. 22, 2021—Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.
Probing statin-associated diseases with genetics
Jul. 12, 2021—Vanderbilt researchers used genetics tools and biobanks with linked electronic health records to explore the associations between statins and noncardiovascular diseases.
Study finds genetic risk factors for severe COVID-19 illness
Jul. 8, 2021—A massive worldwide collaboration including researchers from Vanderbilt University Medical Center (VUMC) has identified several genetic factors associated with SARS-CoV-2 infection and severe COVID-19 illness.
